Ascentage Pharma Reports H1 2025 Financial Results, Shows Strong Growth in Olverembatinib Sales
China-based Ascentage Pharma (NASDAQ: AAPG; HKG: 6855) reported its financial results for the first half...
NASDAQ: AAPG
Ascentage Pharma Collaborates with Major Chinese Firms to Commercialize Lisaftoclax
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced today that it has entered into cooperation...
Ascentage Pharma’s Lisaftoclax Receives NMPA Approval for CLL/SLL Treatment
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that it has received conditional marketing approval...
Ascentage Pharma Highlights Hematology Advances at EHA 2025, Focus on Olverembatinib and APG-5918
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) unveiled 13 research presentations at the 2025 European...
Ascentage Pharma to Present Data on Lisaftoclax and Alrizomadlin at ASCO 2025
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) will present the latest data from two ongoing...
Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) announced that its two innovative drugs have been...
Ascentage Pharma’s Revenue Soars 342% in 2024 on Strong Drug Sales and Partnerships
China-based Ascentage Pharma Group International (NASDAQ: AAPG, HKG: 6855) unveiled its 2024 financials, showing revenues...
Ascentage Pharma Prices US IPO at USD 17.25 per ADS
China-based Ascentage Pharma (NASDAQ: AAPG, HKG: 6855) has announced the pricing of its initial public...